We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Reduces Clinical Hold on Tekmira’s Experimental Ebola Drug
FDA Reduces Clinical Hold on Tekmira’s Experimental Ebola Drug
The FDA has downgraded its clinical hold on Tekmira Pharmaceuticals’ TKM-Ebola experimental RNA interference therapeutic, a move that could clear the way for the drug’s potential use in individuals infected with Ebola virus.